@docrodwong: a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates toge…
Summary
Daraxonrasib received a standing ovation at ASCO as Revolution Medicines' breakthrough against pancreatic cancer, celebrated by over 40,000 oncologists, entrepreneurs, investors, and patient advocates.
View Cached Full Text
Cached at: 06/01/26, 01:25 AM
a standing ovation for daraxonrasib at asco. over 40k oncologists, entrepreneurs, investors, and patient advocates together celebrating revmed’s breakthru in the fight against pancreatic cancer. u never forget these moments. it’s what innovation is all about. https://t.co/lscwBZJL0N
Similar Articles
Research Assistant: AstraZeneca's Agentic System for R&D
AstraZeneca describes Research Assistant, an internal LLM-based multi-agent system that lets scientists explore biomedical data via chat, with evidence grounding and citation links, deployed to 15,000 internal users.
A Modular Agentic Framework for Synthetically Constrained Multi-Objective Hit-to-Lead Optimization
This paper presents SABLE, an open-source agentic framework that uses natural-language orchestration with LLMs to guide synthetically constrained multi-objective hit-to-lead optimization in drug discovery, integrating reaction-templated enumeration, property prediction, and Bayesian optimization.
Multi-Granular Rationale-Guided Molecular LLM for Property Prediction
This paper introduces MR-MoL, a multi-granular rationale-guided molecular LLM that exposes GNN-derived substructure attributions to improve molecular property prediction on MoleculeNet benchmarks.
DoGMA: A Central-Dogma-Guided Foundation Model for Multi-Omics Alignment and Multi-Task Learning in Oncology
DoGMA is a central-dogma-guided foundation model for pan-cancer multi-omics analysis, using a Transformer-MoE architecture with directed attention to align DNA-RNA-protein flows and pretraining via masked hierarchical omics reconstruction. It shows strong performance across cancer representation learning, survival prediction, and metastasis prediction tasks.
@ajassy: Our strategic partnership with Novo Nordisk expands today as they announce that they've chosen AWS as their preferred c…
AWS and Novo Nordisk expand their partnership, with Novo Nordisk selecting AWS as its preferred cloud provider and strategic AI partner to accelerate drug discovery using AI tools like Amazon Bio Discovery and Bedrock AgentCore, plus a co-innovation hub in London.